Practical checks for telehealth platforms and 503A pharmacies, with a California overlay

On September 18, 2026, FDA issued a warning letter to Empower Clinic Services, LLC dba Empower Pharmacy. In addressing compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin products, FDA described their apparent differences from approved products as potentially “pretextual.” The word is striking, but the practical lesson is narrower than a ban on GLP-1 combinations: FDA examined whether the records and production pattern reflected decisions made for individual patients.

What FDA actually found

FDA said Empower's tirzepatide/niacinamide and semaglutide/cyanocobalamin products appeared to be essentially copies of FDA-approved tirzepatide and semaglutide products. Section 503A generally excludes drugs compounded regularly or in inordinate amounts when they are essentially copies of commercially available drugs. The statute excludes from the definition of an “essentially a copy” product a patient-specific change that produces a significant difference for that patient, as determined by the prescriber. 21 U.S.C. § 353a(b)(1)(D), (b)(2).

Three aspects of the letter deserve attention:

·         Volume and repetition. FDA said production volume suggested the differences from approved products were pretextual. That was FDA's inference from the inspected operation, not a numerical ceiling on 503A compounding or a finding that every combination product is prohibited.

·         Prescriber documentation. FDA identified orders without a documented significant-difference determination and others with determinations repeated verbatim across many records. It raised concern that statements appeared to be pre-generated for selection through third-party technology platforms. The letter questions whether those records reflect individualized clinical judgments; it does not declare every electronic menu or repeated phrase invalid.

·         Independent sterility concerns. FDA also cited inadequate dynamic smoke studies, media fills not run under sufficiently challenging conditions, and gaps in accounting for media-fill vials. Insanitary conditions under section 501(a)(2)(A) are a separate issue that does not disappear if a product otherwise qualifies under 503A. The letter separately addresses current good manufacturing practice requirements for products FDA considered outside the 503A exemption.

FDA requested a written response within 15 working days of receipt of its letter.

What the letter changes—and what it does not

FDA's 2018 guidance on essentially copies under section 503A describes how the agency evaluates documented prescriber determinations. The Empower letter illustrates why a pharmacy cannot assume that a recorded statement settles the question when the broader records give reason to question whether the determination was individualized. That is an enforcement signal, not a new statutory burden or an automatic rule that a checkbox fails.

The letter also does not establish a blanket prohibition on adding B12 or niacinamide to a GLP-1 drug. The legal question remains whether the particular compounded product and the particular patient's documented need satisfy applicable law. And while the letter discusses technology platforms supplying pre-selected statements, it is addressed to Empower; it does not find that a named telehealth platform violated the law. Platforms nonetheless have a practical reason to examine how their prescribing interfaces shape the records pharmacies receive.

That issue sits alongside separate FDA scrutiny of GLP-1 marketing. In March 2026, FDA announced warning letters to telehealth companies concerning misleading promotion of compounded products; a June 2026 warning letter provides a further example. Prescribing documentation and advertising should be reviewed as distinct compliance questions.

The California overlay

California's revised compounding regulations became operative October 1, 2025. Article 4.5 (§ 1735 et seq.) concerns nonsterile compounding; Article 4.6 (§ 1736 et seq.) concerns sterile compounding. For sterile preparations, California defines an “essentially a copy” exception around a change for an identified patient that produces a clinically significant difference verified and documented by the pharmacist. That wording should not be confused with federal section 503A's reference to a difference determined by the prescribing practitioner. 16 CCR § 1736(e); 21 U.S.C. § 353a(b)(2).

California also requires sterile-compounding records to be retrievable and maintained with an audit trail for revisions. Its sterile-component rule requires APIs used in compounded sterile preparations to come from an FDA-registered facility, have an evaluated certificate of analysis with specified information, and be suitable for sterile pharmaceutical use. The registered-manufacturer and valid-COA requirements are not uniquely California requirements: federal section 503A already imposes corresponding requirements on bulk drug substances. 16 CCR § 1736.20; 16 CCR § 1736.9(d); 21 U.S.C. § 353a(b)(1)(A).

Nonresident pharmacies serving California should also check the Board of Pharmacy's July 2026 designated-pharmacist requirements, including the California license and employment/work-location conditions, as well as applicable nonresident pharmacy and sterile-compounding permit requirements.

Practical checklist for telehealth platforms

These are risk-reduction measures, not FDA-mandated specifications or thresholds:

1.       Review pre-written justifications. If the interface supplies significant-difference language, assess whether it permits, and the record captures, a genuine patient-specific clinical determination. Consider clinician-authored text with identity and timestamp information rather than treating a default selection as sufficient.

2.       Audit prescribing patterns. Compare formulations and justification language by prescriber and referral source. Repetition warrants review; FDA has not set a percentage at which repetition becomes unlawful.

3.       Examine the sequence of clinical decisions. Check whether the patient's need drives the formulation choice, rather than requiring a clinician to justify a preselected compounded product.

4.       Document the relevant patient-specific difference. Where the compounded product resembles an available approved drug, confirm that the record explains the clinical significance of the change for that patient. Price or convenience alone should not be presented as the patient-specific clinical difference.

5.       Check pharmacy credentials and sourcing records. For California patients, verify applicable nonresident and sterile-compounding authorizations, designated-pharmacist compliance, and API documentation. Identify which party will retain and produce those records.

6.       Review advertising separately. Do not imply that a compounded drug is an FDA-approved generic or equivalent to an approved product. Assess product descriptions against the FDA's 2026 telehealth enforcement concerns.

7.       Review commercial incentives. Examine whether contracts or product-catalog design encourage routine selection of a particular formulation irrespective of patient need. Any separate referral, fee-splitting, or anti-kickback issue requires its own fact-specific legal review.

Practical checklist for 503A pharmacies

1.       Look for uniformity in incoming orders. Review repeated significant-difference language by product, prescriber, and platform; assess the underlying documentation rather than assuming that repetition alone resolves the issue.

2.       Query questionable determinations. If an order lacks a patient-specific determination or its documentation raises a credible concern, seek clarification and retain the exchange before dispensing.

3.       Do not mistake enforcement discretion for permission. FDA's 2018 guidance describes a four or fewer prescriptions per product, per calendar month enforcement policy concerning the “regularly or in inordinate amounts” condition. It is not a general safe harbor or a point below which FDA stops inspecting.

4.       Test the sterile-compounding program. Assess dynamic smoke studies, challenging media-fill simulations, vial accounting, and record integrity against the deficiencies FDA identified in the Empower letter.

5.       Respond to agency findings comprehensively. A warning-letter response should address each observation, corrective action, supporting evidence, and any work still in progress by the deadline specified in the letter.

6.       Keep California records accessible. Confirm applicable permits, designated-pharmacist information, compounding records, API and COA documentation, and procedures for reviewing prescriptions. California's sterile-compounding record rule specifically addresses retrieval and audit trails.

The bottom line

FDA treated production volume and repeated, apparently pre-generated justifications as reasons to question whether compounded products reflected individualized patient needs. The Empower letter does not set a volume cap or ban GLP-1 combinations, but it is a warning against relying on documentation that looks individualized only on paper. The most useful review starts where the clinical choice is made, continues through the pharmacy's prescription and compounding records, and accounts for California's separate sterile-compounding requirements.

This post is attorney advertising and is provided for general information only. It is not legal advice and does not create an attorney-client relationship.